Ticker

Analyst Price Targets — BEAT

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
December 11, 2025 11:41 amYi ChenH.C. Wainwright$5.50$1.91StreetInsider Heartbeam Inc. (BEAT) PT Raised to $5.50 at H.C. Wainwright
December 10, 2025 5:15 pmYi ChenUBS$5.50$1.53TheFly HeartBeam price target raised to $5.50 from $2.50 at H.C. Wainwright
December 8, 2025 11:14 amH.C. Wainwright$2.50$0.73TheFly HeartBeam initiated with a Buy at H.C. Wainwright
October 31, 2025 8:25 amRoth Capital$4.00$1.61TheFly HeartBeam initiated with a Buy at Roth Capital
December 2, 2022 7:58 amIndustrial Alliance Securities$10.00$4.31Benzinga Alliance Global Partners Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $10

Latest News for BEAT

Insider Buying: HeartBeam (NASDAQ:BEAT) Director Purchases $600,000.00 in Stock

HeartBeam, Inc. (NASDAQ: BEAT - Get Free Report) Director Mark Strome acquired 750,000 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was bought at an average price of $0.80 per share, with a total value of $600,000.00. Following the acquisition, the director directly owned 3,650,000 shares in the company, valued

Defense World • Apr 19, 2026
Head to Head Contrast: HeartBeam (NASDAQ:BEAT) versus Enovis (NYSE:ENOV)

HeartBeam (NASDAQ: BEAT - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. Volatility and Risk HeartBeam has a beta of -0.63,

Defense World • Apr 15, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for BEAT.

No House trades found for BEAT.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top